Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 3, 2019, covering events occurring on May 28, 2019, and May 30, 2019. The filing details a refinancing of existing debt held by its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., and new financing arrangements with Sagard Capital Partners, L.P.
Key Financial Metrics and Obligations
- Debt Restructuring: Existing convertible promissory notes totaling approximately $10.5 million were exchanged for two new secured promissory notes.
- Exchange Note 1: Principal amount of $10,535,900.42.
- Exchange Note 2: Principal amount of $2,296,926.16 (representing an exchange fee).
- Total New Principal: $12,832,826.58.
- Interest Rate: 10% per annum on the Exchange Notes.
- Maturity Date: Extended to December 31, 2020.
- New Financing: Issuance of a $500,000 promissory note to Sagard Capital Partners, L.P.
- Warrant Issuance: A 5-year warrant to purchase $375,000 of common stock issued to Sagard.
- Consent Fee: Agreement to pay Sagard $250,000 in cash or $400,000 in stock for consenting to the refinancing.
Material Changes Versus Prior Period
The primary material change is the extension of the maturity date for the Company's significant debt obligations from December 31, 2019, to December 31, 2020. Additionally, the Company incurred a new financial obligation of approximately $2.3 million in the form of Exchange Note 2, which serves as an exchange fee for the refinancing accommodations. The Company also granted a security interest in substantially all of its assets and the assets of its subsidiary to the lender, Chicago Venture Partners, L.P. (CVP).
Guidance, Risks, and Covenants
Covenants: The Exchange Agreement imposes strict covenants, including maintaining NASDAQ listing, timely filing of SEC reports, and restrictions on issuing variable securities or incurring new debt exceeding $100,000 without CVP's consent.
Events of Default and Penalties: The filing outlines extensive events of default, including failure to pay, bankruptcy, or breach of covenants. Upon an Event of Default, CVP may:
- Accelerate the debt.
- Apply a 17.5% penalty multiplier to the outstanding balance.
- Increase the interest rate to 17% per annum.
Liquidity and Contingencies: The consent fee to Sagard is contingent on the closing of an underwritten public offering (Form S-1) or is due by July 31, 2019, if no offering occurs. The Company agreed to use commercially reasonable efforts to ensure the total debt under the Exchange Notes does not exceed the original principal of Exchange Note 1.
Investor Verification Checklist
- Verify the current status of the underwritten public offering required to trigger the Sagard consent fee payment.
- Confirm the Company's ability to maintain NASDAQ listing compliance under the new covenants.
- Review the security agreements to understand the scope of assets pledged to CVP.
- Monitor the Company's cash flow to ensure it can service the 10% interest on the increased principal balance.
- Check for any subsequent filings regarding the $5.5 million note issuance program mentioned in the filing.